Glucagon-receptor activity is associated with increased energy expenditure and reduced liver fat, which is the mechanistic rationale for why retatrutide produced larger weight-loss figures in early trials
Rivus Pharmaceuticals Sector: Oral muscle-sparing therapeutics for obesity and metabolic liver disease HQ: Charlottesville, VA Year Founded: 2019 Origin Story: Rivus Pharmaceuticals was founded around the science of mitochondrial uncoupling, a natural process by which the body dissipates energy by burning fat and sugar without the muscle loss associated with caloric restriction or appetite-suppressing drugs
Semaglutide Phase 3 trials showed approximately 15 to 17% weight loss, while retatrutide Phase 2 data showed up to 24.2%
Results High doses of GLP1-based multi-agonists improve metabolic function in murine models of PCOS We explored metabolic, hormonal, and gonadal responses to different GLP1-based multi-agonists in two experimental (mouse) models of PCOS, namely PWA (postweaning androgenization) and PNA (prenatal androgenization)
Caution is warranted
2-Day Conference Oct 2223, 2026 15.5 Live CEs + 17 bonus CEs CDCES & BC-ADM Exam Prep + Renewal San Diego, CA 1.7 mi from airport Advance Your Expertise and Prepare for Your Future The field of diabetes care is expanding and evolving rapidly